Liposomal Amphotericin B for the Treatment of Systemic Fungal Infections in Patients with Cancer: A Preliminary Study
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Twelve patients with hematologic malignancies complicated by fungal infections were treated with liposomal amphotericin B (L-AmpB). Nine patients were granulocytopenic; the three additional patients with normal granulocyte counts were immunosuppressed. All patients had biopsy findings or cultural evidence of the progression of their fungal infection while being treated with conventional amphotericin B. Doses of 0.8-1.0 mg/kg of L-AmpB were administered intravenously every 24-72 hr. Three patients had a complete remission, five had a partial remission, and four showed no improvements. A total of 161 doses of L-AmpB were administered. Fever and chills occurred on seven occasions. No hematologic or blood chemistry abnormalities related to L-AmpB treatment were observed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chromatographic separation, identification, and analysis of phosphatides
V. Marinetti, G. (1962) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)40442-0 · Cited by 1,079
Causes of death in cancer patients
Inagaki, J., Rodriguez, V., & Bodey, G. P. (1974) · Cancer · doi:10.1002/1097-0142(197402)33:2<568::aid-cncr2820330236>3.0.co;2-2 · Cited by 601
Self-citationCauses of Death in Acute Leukemia: A Ten-Year Study of 414 Patients From 1954-1963.
Hersh, E. M. (1965) · JAMA · doi:10.1001/jama.1965.03090020019005 · Cited by 494
Self-citationEDWARDS, J. E., LEHRER, R. I., STIEHM, E. R., FISCHER, T. J., & YOUNG, L. S. (1978) · Annals of Internal Medicine · doi:10.7326/0003-4819-89-1-91 · Cited by 384
Lopez-Berestein, G., Mehta, R., Hopfer, R. L., Mills, K., Kasi, L., Mehta, K., Fainstein, V., Luna, M., Hersh, E. M., & Juliano, R. (1983) · Journal of Infectious Diseases · doi:10.1093/infdis/147.5.939 · Cited by 303
Self-citationBacteremia and fungemia complicating neoplastic disease
Singer, C., Kaplan, M. H., & Armstrong, D. (1977) · The American Journal of Medicine · doi:10.1016/0002-9343(77)90876-2 · Cited by 284
Liposomal amphotericin B is toxic to fungal cells but not to mammalian cells
Mehta, R., Lopez-Berestein, G., Hopfer, R., Mills, K., & Juliano, R. L. (1984) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(84)90135-4 · Cited by 192
Self-citationLiposome-Encapsulated Amphotericin B for Treatment of Disseminated Candidiasis in Neutropenic Mice
Lopez-Berestein, G., Hopfer, R. L., Mehta, R., Mehta, K., Hersh, E. M., & Juliano, R. L. (1984) · Journal of Infectious Diseases · doi:10.1093/infdis/150.2.278 · Cited by 125
Self-citationClinical pharmacology of 99mTc-labeled liposomes in patients with cancer.
Lopez‐Berestein, G., Kasi, L. P., Rosenblum, M. G., Haynie, T. P., Jahns, M. F., Glenn, H. J., Mehta, R. T., Mavligit, G. M., & Hersh, E. M. (1984) · PubMed · Cited by 117
Self-citationQuantitation of Amphotericin B with Use of High-Pressure Liquid Chromatography
Nilsson-Ehle, I., Yoshikawa, T. T., Edwards, J. E., Schotz, M. C., & GUZE, L. B. (1977) · The Journal of Infectious Diseases · doi:10.1093/infdis/135.3.414 · Cited by 80
Cited by
Liposomal drug delivery systems: From concept to clinical applications
Allen, T. M., & Cullis, P. R. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.037 · Cited by 4,839
Liposome: classification, preparation, and applications
Akbarzadeh, A., Rezaei-Sadabady, R., Davaran, S., Joo, S. W., Zarghami, N., Hanifehpour, Y., Samiei, M., Kouhi, M., & Nejati-Koshki, K. (2013) · Nanoscale Research Letters · doi:10.1186/1556-276x-8-102 · Cited by 3,632
Ribes, J. A., Vanover-Sams, C. L., & Baker, D. J. (2000) · Clinical Microbiology Reviews · doi:10.1128/cmr.13.2.236 · Cited by 1,711
Papahadjopoulos, D., Allen, T. M., Gabizon, A., Mayhew, E., Matthay, K., Huang, S. K., Lee, K. D., Woodle, M. C., Lasic, D. D., & Redemann, C. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.24.11460 · Cited by 1,620
Antifungal and Surgical Treatment of Invasive Aspergillosis: Review of 2,121 Published Cases
Denning, D. W., & Stevens, D. A. (1990) · Clinical Infectious Diseases · doi:10.1093/clinids/12.6.1147 · Cited by 899
Clinical Translation of Nanomedicine
Min, Y., Caster, J. M., Eblan, M. J., & Wang, A. Z. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00116 · Cited by 772
Application of liposomes in medicine and drug delivery
Daraee, H., Etemadi, A., Kouhi, M., Alimirzalu, S., & Akbarzadeh, A. (2016) · Artificial Cells, Nanomedicine, and Biotechnology · doi:10.3109/21691401.2014.953633 · Cited by 765
How do the polyene macrolide antibiotics affect the cellular membrane properties?
Bolard, J. (1986) · Biochimica et Biophysica Acta (BBA) - Reviews on Biomembranes · doi:10.1016/0304-4157(86)90002-x · Cited by 750
Engineering liposomes for drug delivery: progress and problems
Gregoriadis, G. (1995) · Trends in Biotechnology · doi:10.1016/s0167-7799(00)89017-4 · Cited by 626
Survival factors in rhino-orbital-cerebral mucormycosis
Yohai, R. A., Bullock, J. D., Aziz, A. A., & Markert, R. J. (1994) · Survey of Ophthalmology · doi:10.1016/s0039-6257(05)80041-4 · Cited by 492
Lipid Formulations of Amphotericin B: Recent Progress and Future Directions
Hiemenz, J. W., & Walsh, T. J. (1996) · Clinical Infectious Diseases · doi:10.1093/clinids/22.supplement_2.s133 · Cited by 404
Lipid Formulations of Amphotericin B: Clinical Efficacy and Toxicities
Wong-Beringer, A., Jacobs, R. A., & Guglielmo, B. J. (1998) · Clinical Infectious Diseases · doi:10.1086/514704 · Cited by 395
Hepatic Candidiasis in Cancer Patients: The Evolving Picture of the Syndrome
THALER, M., PASTAKIA, B., SHAWKER, T. H., O'LEARY, T., & PIZZO, P. A. (1988) · Annals of Internal Medicine · doi:10.7326/0003-4819-108-1-88 · Cited by 395
Groll, A. H., Piscitelli, S. C., & Walsh, T. J. (1998) · Advances in pharmacology · doi:10.1016/s1054-3589(08)60129-5 · Cited by 377
Antifungal agents: An overview. Part I
Gupta, A. K., Sauder, D. N., & Shear, N. H. (1994) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(08)81495-8 · Cited by 369
Liposomes: A Review of Manufacturing Techniques and Targeting Strategies
Maherani, B., Arab-Tehrany, E., R. Mozafari, M., Gaiani, C., & Linder, M. (2011) · Current Nanoscience · doi:10.2174/157341311795542453 · Cited by 369
It only takes one to do many jobs: Amphotericin B as antifungal and immunomodulatory drug
Mesa-Arango, A. C., Scorzoni, L., & Zaragoza, O. (2012) · Frontiers in Microbiology · doi:10.3389/fmicb.2012.00286 · Cited by 311
“For this reason, new formulations have been introduced in the last years (Lopez-Berestein et al., 1985; Bohme and Hoelzer, 1996; Gulati et al., 1998; Rust and Jameson, 1998; Walsh et al., 1998; Dupont, 2002).”
BackgroundCarrier effects on biological activity of amphotericin B
Brajtburg, J., & Bolard, J. (1996) · Clinical Microbiology Reviews · doi:10.1128/cmr.9.4.512 · Cited by 310
The Multirole of Liposomes in Therapy and Prevention of Infectious Diseases
Nisini, R., Poerio, N., Mariotti, S., De Santis, F., & Fraziano, M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00155 · Cited by 296
Vincent, J. L., Anaissie, E., Bruining, H., Demajo, W., El-Ebiary, M., Haber, J., Hiramatsu, Y., Nitenberg, G., Nyström, P. O., Pittet, D., et al. (1998) · Intensive Care Medicine · doi:10.1007/s001340050552 · Cited by 277
Liposomal and Lipid Formulations of Amphotericin B: Clinical Pharmacokinetics
Janknegt, R., de Marie, S., Bakker-Woudenberg, I. A. J. M., & Crommelin, D. J. A. (1992) · Clinical Pharmacokinetics · doi:10.2165/00003088-199223040-00004 · Cited by 274
New Spectrum of Fungal Infections in Patients with Cancer
Anaissie, E., Bodey, G. P., Kantarjian, H., Ro, J., Vartivarian, S. E., Hopfer, R., Hoy, J., & Rolston, K. (1989) · Clinical Infectious Diseases · doi:10.1093/clinids/11.3.369 · Cited by 259
Self-citationThe accumulation of drugs within large unilamellar vesicles exhibiting a proton gradient: a survey
Madden, T. D., Harrigan, P. R., Tai, L. C. L., Bally, M. B., Mayer, L. D., Redelmeier, T. E., Loughrey, H. C., Tilcock, C. P. S., Reinish, L. W., & Cullis, P. R. (1990) · Chemistry and Physics of Lipids · doi:10.1016/0009-3084(90)90131-a · Cited by 255
Liposomes as Potential Drug Carrier Systems for Drug Delivery
Çağdaş, M., Sezer, A. D., & Bucak, S. (2014) · Application of Nanotechnology in Drug Delivery · doi:10.5772/58459 · Cited by 245
Antimicrobial Peptides and Nanotechnology, Recent Advances and Challenges
Biswaro, L. S., da Costa Sousa, M. G., Rezende, T. M. B., Dias, S. C., & Franco, O. L. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.00855 · Cited by 227
“These include liposomes (Bangham et al., 1965; Lopez-Berestein et al., 1985; Lasic, 1998; Torchilin, 2007; Haley and Frenkel, 2008; Steichen et al., 2013), micelles (Lavasanifar et al., 2002; Moghimi et al., 2005; Mu et al., 2005; Liechty and Peppas, 2012) dendrimers (Hughes, 2005; Majoros et al.,…”
BackgroundUnusual lipid structures selectively reduce the toxicity of amphotericin B.
Janoff, A. S., Boni, L. T., Popescu, M. C., Minchey, S. R., Cullis, P. R., Madden, T. D., Taraschi, T., Gruner, S. M., Shyamsunder, E., & Tate, M. W. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.16.6122 · Cited by 223
Treatment of hepatosplenic candidiasis with liposomal-amphotericin B.
Lopez-Berestein, G., Bodey, G. P., Frankel, L. S., & Mehta, K. (1987) · Journal of Clinical Oncology · doi:10.1200/jco.1987.5.2.310 · Cited by 216
Self-citationSharkey, P. K., Graybill, J. R., Johnson, E. S., Hausrath, S. G., Pollard, R. B., Kolokathis, A., Mildvan, D., Fan-Havard, P., Eng, R. H. K., Patterson, T. F., et al. (1996) · Clinical Infectious Diseases · doi:10.1093/clinids/22.2.315 · Cited by 197
Amphotericin B lipid complex therapy of experimental fungal infections in mice
Clark, J. M., Whitney, R. R., Olsen, S. J., George, R. J., Swerdel, M. R., Kunselman, L., & Bonner, D. P. (1991) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.35.4.615 · Cited by 159
“Lopez-Berestein and coworkers (12-16) have used DMPC, DMPG, and AmB in large multilamellar liposomes (over 1 ,um in diameter).”
BackgroundMethodInfluentialVan t Wout, J. W., Mattie, H., & van Furth, R. (1989) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.33.2.147 · Cited by 72
Metadata
- Authors
- Lopez-Berestein, G., Fainstein, V., Hopfer, R., Mehta, K., Sullivan, M. P., Keating, M., Rosenblum, M. G., Mehta, R., Luna, M., Hersh, E. M., Reuben, J., Juliano, R. L., & Bodey, G. P.
- Venue
- Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 1985-04-01
- Volume
- 151
- Issue
- 4
- Pages
- 704-710
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- OpenAlex
- W2065464305
- Cited by
- 405
- References
- 11
- FWCI
- 30.22
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.